logo
State of the Journal: 2011
GPC5 Gene and Its Related Pathways in Lung Cancer
Measures of Interrater Agreement
Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small Cell Lung Carcinoma
Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
Increased Lung Cancer Risk among Patients with Pulmonary Tuberculosis
Exercise Capacity, Lung Function, and Quality of Life After Interventional Bronchoscopy
Positron Emission Tomography/Computed Tomography and Lymphovascular Invasion Predict Recurrence in Stage I Lung Cancers
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer
A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer
Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer
Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation Paclitaxel-Carboplatin in Stage III Non-small Cell Lung Cancer
Positron Emission Tomography with 18Fluorodeoxyglucose in Radiation Treatment Planning for Non-small Cell Lung Cancer
Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials
Sex Differences in Outcome with Bevacizumab Therapy
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years
Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer
Comparison of Nedaplatin and Irinotecan for Patients with Squamous and Nonsquamous Cell Carcinoma of the Lung
Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer
Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer
Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer
Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer
Pilot Study of 1650-G
Maintenance Therapy in Advanced Non-small Cell Lung Cancer
Polymorphisms in the Apoptotic Pathway Gene BCL-2 and Survival in Small Cell Lung Cancer
The Use of Pleural Fluid sCD44v6/std Ratio for Distinguishing Mesothelioma from Other Pleural Malignancies
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer
Miliary Never-Smoking Adenocarcinoma of the Lung
How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples
Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer
The Role of Tumor Stroma in Cancer Progression and Prognosis
Small Cell Lung Cancer in a 26-Year-Old Man with Significant Cannabis Exposure
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma
Best of the Month
Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology
ERCC2/XPD Polymorphisms and Lung Cancer Risk
ERCC2/XPD Polymorphisms and Lung Cancer Risk